Core Viewpoint - Hubei Hongyuan Pharmaceutical Technology Co., Ltd. is undergoing a review of its stock incentive plan, ensuring compliance with relevant regulations and internal governance standards [1][2]. Compliance with Listing Company Requirements - The financial report for the most recent accounting year did not receive a negative opinion or inability to express an opinion from the registered accountant [1]. - There have been no instances in the last 36 months where profit distribution was not conducted according to laws, regulations, or company articles [1]. Compliance of Incentive Objects - The incentive plan does not include shareholders holding more than 5% of the company's shares [1]. - No inappropriate candidates have been identified by the China Securities Regulatory Commission (CSRC) in the last 12 months [1]. Compliance of Incentive Plan - The total number of shares involved in all effective stock incentive plans does not exceed 20% of the company's total share capital [1]. - The proposed number of rights to be granted does not exceed 20% of the total rights intended for this stock incentive plan [1]. Disclosure Completeness of Incentive Plan - The purpose of the stock incentive plan and the basis for determining the incentive objects have been clearly stated [3]. - The plan includes details on the number of rights to be granted and their proportion to the company's total share capital [3]. Performance Assessment Indicators - Performance assessment indicators are required to be objective, clear, and beneficial for enhancing the company's competitiveness [5]. - At least three comparable companies from the same industry should be selected as benchmarks for these indicators [5]. Lock-up and Vesting Period Compliance - The interval between the authorization date of restricted stocks and the first lifting of restrictions must be no less than one year [7]. - The proportion of shares released from restrictions in each period must not exceed 50% of the total restricted stocks granted to the incentive objects [7].
宏源药业: 2025年限制性股票激励计划自查表